VANCOUVER, British Columbia--(BUSINESS WIRE)--Dr. John Todd, president and CEO of ProtoKinetix, Inc. (OTCBB:PKTX),
announces today the results of a series of tests conducted by ITTEC Stem
laboratory in Montreal. These results confirm that AAGP™
reduces inflammation.
For the first time, AAGP™ is shown to have an
effect on a signaling/molecular pathway. This pathway is known to be
involved in an inflammatory reaction, angiogenesis (development of blood
vessels) and in the development of malignancies. Research work done to
date demonstrates that even as the intensity of the inflammatory
stimulus was increased, the efficacy of AAGP™
as an anti-inflammatory agent was still present.
This exciting new development has opened up several additional
opportunities for research and business development. The full report is
available for viewing at: www.protokinetix.com.
About ProtoKinetix:
ProtoKinetix, Inc. is a Biotechnical Company dedicated to the
development of a family of synthetic antifreeze glycoproteins (AAGP™)
for human and veterinary medicine, the bio technology and cosmetic
industries, and as a food additive. Using previously published research
on native antifreeze proteins and antifreeze glycoproteins as a guide,
and coordinating a vast pool of world recognized intellectual talent in
a networked environment, PKTX is conducting rapid and meaningful
research with a view to developing markets for this very useful family
of molecules. Sign up for free automatic email news alerts at our new
website at: www.protokinetix.com.
The Private Securities LitigationReform Act of 1995 provides
a “safe harbor” for
forward-looking statements. Some information included in this press
release contains statements that are forward-looking. Such
forward-looking information involves significant risks and uncertainties
that could affect anticipated results in the future and, accordingly,
these results may differ materially from those expressed in any
forward-looking statements made by or on behalf of the Company. For a
description of additional risks and uncertainties, please refer to the
Company’s filings with the Securities and
Exchange Commission.
On behalf of the Board of DirectorsDr. John Todd - President
